TABLE 3.
Safety assessment reported by volunteers within 2 months of the trial.
| Symptoms | All (n = 50) | Control (n = 25) | 250 mg OPP (n = 25) | p |
|---|---|---|---|---|
| None reported | 7 | 5 | 2 | 0.417 |
| Bloated | 1 | 0 | 1 | 1.000 |
| Easy to defecate | 13 | 6 | 7 | 0.747 |
| Get hungry easily | 9 | 5 | 4 | 1.000 |
| Lightheaded | 4 | 2 | 2 | 1.000 |
| Lose weight easily | 5 | 3 | 2 | 1.000 |
| More energetic | 7 | 3 | 4 | 1.000 |
| Reduce menstrual pain | 1 | 0 | 1 | 1.000 |
| Short menstrual duration | 2 | 0 | 2 | 0.490 |
| Sleepiness | 1 | 1 | 0 | 1.000 |
Data are tabulated as frequency, n (%).